Oak Ridge, TN -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology. The study is being conducted under the leadership of Avindra Nath, M.D. at the National Institute of Neurological Disorders and Stroke (NINDS) located in Bethesda, Maryland.
Dr. David S. Goldstein, M.D., Ph.D., Lead Associate Investigator, NINDS, commented, “One of the mysteries of post-acute sequelae SARS-CoV-2 is the basis for non-specific, enduring, debilitating symptoms such as ‘brain fog’ executive dysfunction, exercise intolerance, and orthostatic intolerance. There are several potential mechanisms, including low blood volume. The 131I-albumin technique is a well-established method for measuring blood volume.
“We are honored to collaborate with such an esteemed group of investigators at one of the most important medical research centers in the world to provide unique medical insights into what may be affecting thousands suffering from ‘Long Haul’ COVID-19. BVA is used daily at leading hospital centers to treat patients and for groundbreaking medical research because of its unique accuracy and clinical utility,” said Michael Feldschuh, CEO and President of Daxor Corporation.
Daxor’s BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure. Daxor is currently under contract with the Department of Defense to develop a portable next-generation blood volume analyzer capable of faster measurement and a unique, patent-pending fluorescence technology.
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.